Literature DB >> 26822925

Thyroid cancer: Use of MDSC to assess malignancy.

Claire Greenhill.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26822925     DOI： 10.1038/nrendo.2016.10

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Authors:  Trevor E Angell; Melissa G Lechner; Alison M Smith; Sue E Martin; Susan G Groshen; Dennis R Maceri; Peter A Singer; Alan L Epstein
Journal:  Thyroid       Date:  2016-02-10       Impact factor: 6.568
  1 in total
  3 in total

Review 1.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy.

Authors:  Minghe Lv; Xibing Zhuang; Shali Shao; Xuan Li; Yunfeng Cheng; Duojiao Wu; Xiangdong Wang; Tiankui Qiao
Journal:  J Immunol Res       Date:  2022-07-26       Impact factor: 4.493

Review 3.  Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer.

Authors:  Chao Zhang; Shuo Wang; Yufeng Liu; Cheng Yang
Journal:  Oncotarget       Date:  2016-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.